Cytosorbents (NASDAQ:CTSO) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research report report published on Monday. The brokerage issued a hold rating on the medical research company’s stock.

A number of other analysts have also recently weighed in on CTSO. HC Wainwright restated a “neutral” rating and set a $1.00 target price on shares of Cytosorbents in a report on Monday, November 11th. EF Hutton Acquisition Co. I upgraded Cytosorbents to a “strong-buy” rating in a research report on Monday, July 29th.

Cytosorbents Price Performance

Shares of NASDAQ CTSO opened at $0.90 on Monday. The firm has a 50-day moving average of $1.12 and a two-hundred day moving average of $1.01. The company has a market capitalization of $49.00 million, a price-to-earnings ratio of -2.49 and a beta of 0.56. The company has a current ratio of 1.97, a quick ratio of 1.58 and a debt-to-equity ratio of 1.06. Cytosorbents has a twelve month low of $0.70 and a twelve month high of $2.15.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in CTSO. CM Management LLC lifted its position in shares of Cytosorbents by 3.0% in the 2nd quarter. CM Management LLC now owns 850,000 shares of the medical research company’s stock valued at $598,000 after acquiring an additional 25,000 shares in the last quarter. Geode Capital Management LLC raised its stake in Cytosorbents by 7.5% during the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after purchasing an additional 32,415 shares during the period. Atomi Financial Group Inc. purchased a new stake in shares of Cytosorbents in the third quarter valued at $51,000. Sargent Investment Group LLC boosted its position in shares of Cytosorbents by 4.9% in the second quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock worth $1,008,000 after buying an additional 67,181 shares during the period. Finally, Avenir Corp grew its holdings in shares of Cytosorbents by 4.0% during the first quarter. Avenir Corp now owns 3,172,696 shares of the medical research company’s stock valued at $3,014,000 after buying an additional 121,294 shares in the last quarter. 32.87% of the stock is currently owned by institutional investors and hedge funds.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.